Paraneoplastik Sendrom ve Opsoklonus Miyoklonus Sendromu

Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010 Sep;85(9):838-54. doi: 10.4065/mcp.2010.0099. Erratum in: Mayo Clin Proc. 2011 Apr;86(4):364. Dosage error in article text. PMID: 20810794; PMCID: PMC2931619.

Marsili L, Marcucci S, LaPorta J, Chirra M, Espay AJ, Colosimo C. Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment. Biomedicines. 2023 May 9;11(5):1406. doi: 10.3390/biomedicines11051406. PMID: 37239077; PMCID: PMC10216177.

Gilligan M, McGuigan C, McKeon A. Paraneoplastic Neurologic Disorders. Curr Neurol Neurosci Rep. 2023 Mar;23(3):67-82. doi: 10.1007/s11910-023-01250-w. Epub 2023 Feb 13. PMID: 36781586; PMCID: PMC10011323.

Binks S, Uy C, Honnorat J, Irani SR. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2022 Feb;22(1):19-31. doi: 10.1136/practneurol-2021-003073. Epub 2021 Sep 11. PMID: 34510016.

Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):e1014. doi: 10.1212/NXI.0000000000001014. PMID: 34006622; PMCID: PMC8237398.

Sardiña González C, Martínez Vivero C, López Castro J. Paraneoplastic syndromes review: The great forgotten ones. Crit Rev Oncol Hematol. 2022 Jun;174:103676. doi: 10.1016/j.critrevonc.2022.103676. Epub 2022 Apr 2. PMID: 35378267.

Barbagallo M, Vitaliti G, Pavone P, Romano C, Lubrano R, Falsaperla R. Pediatric Autoimmune Encephalitis. J Pediatr Neurosci. 2017 Apr-Jun;12(2):130-134. doi: 10.4103/jpn.JPN_185_16. PMID: 28904568; PMCID: PMC5588635.

Honnorat J, Didelot A, Karantoni E, Ville D, Ducray F, Lambert L, Deiva K, Garcia M, Pichit P, Cavillon G, Rogemond V, DeLattre JY, Tardieu M. Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology. 2013 Jun 11;80(24):2226-32. doi: 10.1212/WNL.0b013e318296e9c3. Epub 2013 May 8. PMID: 23658383.

Braczkowski M, Soszyński D, Sierakowska A, Braczkowski R, Kufel K, Łabuz-Roszak B. Autoimmune Encephalitis with Antibodies: Anti-NMDAR, Anti-AMPAR, Anti-GQ1b, Anti-DPPX, Anti-CASPR2, Anti-LGI1, Anti-RI, Anti-Yo, Anti-Hu, Anti-CV2 and Anti-GABAAR, in the Course of Psychoses, Neoplastic Diseases, and Paraneoplastic Syndromes. Diagnostics (Basel). 2023 Aug 3;13(15):2589. doi: 10.3390/diagnostics13152589. PMID: 37568953; PMCID: PMC10417199.

Kunchok A, McKeon A, Zekeridou A, Flanagan EP, Dubey D, Lennon VA, Klein CJ, Mills JR, Pittock SJ. Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clin Proc. 2022 Mar;97(3):547-559. doi: 10.1016/j.mayocp.2021.07.023. Epub 2021 Dec 23. PMID: 34955239.

Ibrahim Ismail I, K John J, Ibrahim M, Al-Hashel JY. Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent. Case Rep Neurol. 2020 Feb 5;12(1):50-55. doi: 10.1159/000505232. PMID: 32110228; PMCID: PMC7036575.

Chatham M, Niravath P. Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration: Case Series and Review of Literature. Cureus. 2021 Dec 6;13(12):e20203. doi: 10.7759/cureus.20203. PMID: 35004023; PMCID: PMC8727331.

Rossor T, Yeh EA, Khakoo Y, Angelini P, Hemingway C, Irani SR, Schleiermacher G, Santosh P, Lotze T, Dale RC, Deiva K, Hero B, Klein A, de Alarcon P, Gorman MP, Mitchell WG, Lim M; OMS Study Group. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Neurol Neuroimmunol Neuroinflamm. 2022 Mar 8;9(3):e1153. doi: 10.1212/NXI.0000000000001153. PMID: 35260471; PMCID: PMC8906188.

Rudnicki SA, Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle Nerve. 2000 Dec;23(12):1800-18. doi: 10.1002/1097-4598(200012)23:12<1800::aid-mus3>3.0.co;2-x. PMID: 11102903.

Medeiros LM, Morais TC, Primo AEL, Speltri VC, Rocha MSG. Stiff-Person Syndrome and Graves' Disease: A Pediatric Case Report. Child Neurol Open. 2016 Dec 15;3:2329048X16684397. doi: 10.1177/2329048X16684397. PMID: 28503622; PMCID: PMC5417285.

Dalakas MC. Stiff Person Syndrome and GAD Antibody-Spectrum Disorders. Continuum (Minneap Minn). 2024 Aug 1;30(4):1110-1135. doi: 10.1212/CON.0000000000001457. PMID: 39088290.

Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, Gadoth A, Naddaf E, McKeon A, Pittock SJ, Zalewski NL. Clinical spectrum of high-titre GAD65 antibodies. J Neurol Neurosurg Psychiatry. 2021 Feb 9;92(6):645–54. doi: 10.1136/jnnp-2020-325275. Epub ahead of print. PMID: 33563803; PMCID: PMC8142435.

Chalk CH, Windebank AJ, Kimmel DW, McManis PG. The distinctive clinical features of paraneoplastic sensory neuronopathy. Can J Neurol Sci / J Can Sci Neurol. 1992;19:346–51.

Graus F, Vincent A, Pozo-Rosich P, et al. Anti-glial nuclear antibody:marker of lung cancerrelated paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165(1-2):166-171.

Swafford C, Roach ES. Juvenile Dermatomyositis and the Inflammatory Myopathies. Semin Neurol. 2020 Jun;40(3):342-348. doi: 10.1055/s-0040-1705120. Epub 2020 Apr 6. PMID: 32252099.

Zhou J, Jin M, Su Y, Zhuo X, Fu L, Ren X, Ren C, Zhou A, Li J, Zhang W. Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood. Neurol Neuroimmunol Neuroinflamm. 2024 May;11(3):e200242. doi: 10.1212/NXI.0000000000200242. Epub 2024 Apr 24. PMID: 38657195; PMCID: PMC11087047.

Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C. Imaging of autoimmune encephalitis--Relevance for clinical practice and hippocampal function. Neuroscience. 2015 Nov 19;309:68-83. doi: 10.1016/j.neuroscience.2015.05.037. Epub 2015 May 23. PMID: 26012492.

McKeon A, Ahlskog JE, Britton JW, Lennon VA, Pittock SJ. Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol. 2009 Feb;66(2):268-71. doi: 10.1001/archneurol.2008.556. Erratum in: Arch Neurol. 2011 Mar;68(3):371. Britton, Jeffrey A [corrected to Britton, Jeffrey W]. PMID: 19204167.

Deng B, Cai M, Qiu Y, Liu X, Yu H, Zhang X, Huang H, Zhao X, Yang W, Dong S, Jin L, Chu S, Chen X. MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor: A Case Series. Neurol Neuroimmunol Neuroinflamm. 2022 Mar 25;9(3):e1158. doi: 10.1212/NXI.0000000000001158. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2022 Sep 7;9(6):e200040. doi: 10.1212/NXI.0000000000200040. PMID: 35338092; PMCID: PMC8958939.

Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019 Nov;18(11):1045-1057. doi: 10.1016/S1474-4422(19)30244-3. Epub 2019 Jul 17. PMID: 31326280.

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20. PMID: 26906964; PMCID: PMC5066574.

Hsu M, Tejani I, Shah N, Olaosebikan R, Kumar A, Naik S. Review of Opsoclonus-Myoclonus Ataxia Syndrome in Pediatric Patients. Children (Basel). 2024 Mar 19;11(3):367. doi: 10.3390/children11030367. PMID: 38539402; PMCID: PMC10968807.

Pranzatelli MR, Tate ED, McGee NR. Multifactorial analysis of opsoclonusmyoclonus syndrome etiology (“Tumor” vs. “No tumor”) in a cohort of 356 US children. Pediatr Blood Cancer 2018;65:e27097.

Armangue T, Titulaer MJ, Sabater L, et al A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol 2014;75(3):435-441.

Emamikhah M, Babadi M, Mehrabani M, et al Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: case series and review of literature. J Neurovirol 2021;27(1):26-34.

Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol 2017;8(September):153-158.

Matthay KK, Blaes F, Hero B, et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. In: Cancer Letters. Vol 228. Ireland: Cancer Lett; 2005:275-282. doi: 10.1016/j.canlet.2005.01.051

Anand G, Bridge H, Rackstraw P, et al Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome. Dev Med Child Neurol 2015;57(3): 265-272.

Brunklaus A, Pohl K, Zuberi SM, De Sousa C. Investigating neuroblastoma in childhood opsoclonus-myoclonus syndrome. Arch Dis Child 2012;97(5):461-463.

Bleeker G, Tytgat GAM, Adam JA, et al 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev 2015;2015(9): CD009263

Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol. 2017;8:468. doi: 10.3389/fneur.2017.00468

Gorman MP. Update on diagnosis, treatment, and prognosis in opsoclonusmyoclonus- ataxia syndrome. Curr Opin Pediatr 2010;22(6):745-750.

Wilbur C, Yea C, Licht C, Irwin MS, Yeh EA. An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. Pediatr Blood Cancer 2019; 66(8):e27776.

Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol 2017;30(3):334-344.

Wilbur C, Yea C, Licht C, Irwin MS, Yeh EA. An upfront immunomodulatory therapy protocol for pediatric opsoclonus-myoclonus syndrome. Pediatr Blood Cancer 2019; 66(8):e27776.

Mitchell WG, Wooten AA, O’Neil SH, Rodriguez JG, Cruz RE, Wittern R. Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS). J Child Neurol 2015;30(8):976-982.

De Grandis E, Parodi S, Conte M, et al Long-term follow-up of neuroblastoma associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009;40(3): 103-111.

Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109(1):86-98.

Mitchell WG, Brumm VL, Azen CG, Patterson KE, Aller SK, Rodriguez J. Longitudinal neurodevelopmental evaluation of children with opsoclonus-ataxia. Pediatrics 2005;116(4):901-907.